Buloxibutid

Generic Name: Buloxibutid

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₉N_₃O_₄S_₂

CAS Number: 477775-14-7

Unique Ingredient Identifier: RC2V4W0EYC

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Idiopathic pulmonary fibrosis promising drugs: FOXO3 and beyond

Refoxy Pharma secures $9.58 million to develop IPF drug RP-01 targeting FOXO3. Boehringer Ingelheim plans NDA submission for nerandomilast. Insilico's ISM001-055 and Endeavor's ENV-101 show disease improvement. Vicore's buloxibutid and BMS' BMS-986278 also chart progress. Pliant's bexotegrast mitigates chronic cough in IPF. IPOs and partnerships fuel IPF therapeutic field.

pharmaceutical-technology.com

3 months ago

Boehringer seeks approval for lung fibrosis drug following Phase III win

Boehringer Ingelheim seeks approval for nerandomilast after Phase III trial in idiopathic pulmonary fibrosis met primary endpoint. The trial, FIBRONEER-IPF, improved forced vital capacity after 52 weeks. Nerandomilast, a PDE4B inhibitor, received breakthrough therapy designation in 2022 and is also being tested in progressive fibrosing interstitial lung diseases.

Related Clinical Trials:

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy